These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27809255)

  • 1. Mono-PEGylation of Alpha-MMC and MAP30 from Momordica charantia L.: Production, Identification and Anti-Tumor Activity.
    Sun Y; Sun F; Li J; Wu M; Fan X; Meng Y; Meng Y
    Molecules; 2016 Oct; 21(11):. PubMed ID: 27809255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of an antitumor and antivirus agent: chemical modification of α-MMC and MAP30 from Momordica Charantia L. with covalent conjugation of polyethyelene glycol.
    Meng Y; Liu S; Li J; Meng Y; Zhao X
    Int J Nanomedicine; 2012; 7():3133-42. PubMed ID: 22802682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel method for simultaneous production of two ribosome-inactivating proteins, α-MMC and MAP30, from Momordica charantia L.
    Meng Y; Lin S; Liu S; Fan X; Li G; Meng Y
    PLoS One; 2014; 9(7):e101998. PubMed ID: 25003606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Α-MMC and MAP30, two ribosome-inactivating proteins extracted from Momordica charantia, induce cell cycle arrest and apoptosis in A549 human lung carcinoma cells.
    Fan X; He L; Meng Y; Li G; Li L; Meng Y
    Mol Med Rep; 2015 May; 11(5):3553-8. PubMed ID: 25573293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEGylation alleviates the non-specific toxicities of Alpha-Momorcharin and preserves its antitumor efficacy in vivo.
    Deng NH; Wang L; He QC; Zheng JC; Meng Y; Meng YF; Zhang CJ; Shen FB
    Drug Deliv; 2016; 23(1):95-100. PubMed ID: 24786488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribosome inactivating proteins (RIPs) from Momordica charantia for anti viral therapy.
    Puri M; Kaur I; Kanwar RK; Gupta RC; Chauhan A; Kanwar JR
    Curr Mol Med; 2009 Dec; 9(9):1080-94. PubMed ID: 19747115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribosome-inactivating Protein MAP30 Isolated from
    Zhou Y; Yang D; Qiang Z; Meng Y; Li R; Fan X; Zhao W; Meng Y
    Recent Pat Anticancer Drug Discov; 2024; 19(2):223-232. PubMed ID: 36330636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and purification of a recombinant ELRL-MAP30 with dual-targeting anti-tumor bioactivity.
    Chen WW; Zhang HR; Huang ZG; Zhou ZY; Lou QW; Jiang XY; Zhu ZH
    Protein Expr Purif; 2021 Sep; 185():105893. PubMed ID: 33933613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PEGylation is effective in reducing immunogenicity, immunotoxicity, and hepatotoxicity of α-momorcharin in vivo.
    Zheng JC; Lei N; He QC; Hu W; Jin JG; Meng Y; Deng NH; Meng YF; Zhang CJ; Shen FB
    Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):866-73. PubMed ID: 22439816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor activity and immunological modification of ribosome-inactivating protein (RIP) from Momordica charantia by covalent attachment of polyethylene glycol.
    Li M; Chen Y; Liu Z; Shen F; Bian X; Meng Y
    Acta Biochim Biophys Sin (Shanghai); 2009 Sep; 41(9):792-9. PubMed ID: 19727528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunoaffinity purification of α-momorcharin from bitter melon seeds (Momordica charantia).
    Yao X; Li J; Deng N; Wang S; Meng Y; Shen F
    J Sep Sci; 2011 Nov; 34(21):3092-8. PubMed ID: 21994203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemosynthesis and characterization of site-specific N-terminally PEGylated Alpha-momorcharin as apotential agent.
    Sun W; Sun J; Zhang H; Meng Y; Li L; Li G; Zhang X; Meng Y
    Sci Rep; 2018 Dec; 8(1):17729. PubMed ID: 30531997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAP30 protein from Momordica charantia is therapeutic and has synergic activity with cisplatin against ovarian cancer in vivo by altering metabolism and inducing ferroptosis.
    Chan DW; Yung MM; Chan YS; Xuan Y; Yang H; Xu D; Zhan JB; Chan KK; Ng TB; Ngan HY
    Pharmacol Res; 2020 Nov; 161():105157. PubMed ID: 32814169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-momorcharin (α-MMC) exerts effective anti-human breast tumor activities but has a narrow therapeutic window in vivo.
    Cao D; Sun Y; Wang L; He Q; Zheng J; Deng F; Deng S; Chang S; Yu X; Li M; Meng Y; Jin J; Shen F
    Fitoterapia; 2015 Jan; 100():139-49. PubMed ID: 25447153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAP30 and luffin-α: Novel ribosome-inactivating proteins induce plant systemic resistance against plant viruses.
    Wei Z; Yang L; Liu W; Xu X; Ran M; Jin Y; Sun X
    Pestic Biochem Physiol; 2023 Apr; 191():105342. PubMed ID: 36963924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of a Recombinant Anti-HIV and Anti-Tumor Protein, MAP30, in Nicotiana tobacum Hairy Roots: A pH-Stable and Thermophilic Antimicrobial Protein.
    Moghadam A; Niazi A; Afsharifar A; Taghavi SM
    PLoS One; 2016; 11(7):e0159653. PubMed ID: 27459300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant expression and purification of a MAP30-cell penetrating peptide fusion protein with higher anti-tumor bioactivity.
    Lv Q; Yang XZ; Fu LY; Lu YT; Lu YH; Zhao J; Wang FJ
    Protein Expr Purif; 2015 Jul; 111():9-17. PubMed ID: 25797209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of recombinant ribosome inactivating protein MAP30 in E.coli and its biological activity].
    Zhang LL; Ding Q; Zhan JB
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 May; 39(3):264-71. PubMed ID: 20544988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ribosome-Inactivating Protein α-Momorcharin Derived from Edible Plant
    Chen YJ; Zhu JQ; Fu XQ; Su T; Li T; Guo H; Zhu PL; Lee SK; Yu H; Tse AK; Yu ZL
    Toxins (Basel); 2019 Nov; 11(12):. PubMed ID: 31779275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MAP30 protein from bitter gourd (Momordica charantia) seeds promotes apoptosis in liver cancer cells in vitro and in vivo.
    Fang EF; Zhang CZ; Wong JH; Shen JY; Li CH; Ng TB
    Cancer Lett; 2012 Nov; 324(1):66-74. PubMed ID: 22579806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.